Mold-Tek Packaging (533080) Q1 26/27 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 26/27 earnings summary
10 Sep, 2026Executive summary
Achieved record quarterly turnover exceeding ₹300 crore, with YoY revenue growth of 24.90% and sequential growth of 26.32%, driven by strong demand in pharma, food, FMCG, and paints.
EBITDA per kg reached an all-time high of ₹46.68, up from ₹41.64 YoY, reflecting operational efficiencies, product mix improvements, and Hyderabad unit consolidation.
PAT increased to ₹25.57 crore, up 14.19% YoY and 23.89% sequentially, with EPS rising to 7.70.
Sales volume grew 6.25% YoY and 5.82% sequentially, led by pharma and FMCG.
Consolidation of Hyderabad units and automation initiatives significantly reduced overheads and improved margins.
Financial highlights
Q1 FY27 revenue from operations was ₹300.45 crore, up from ₹240.56 crore in Q1 FY26 (24.90% growth).
EBITDA for Q1 FY27 was ₹56.43 crore, up from ₹47.38 crore YoY (19.11% growth).
PAT for Q1 FY27 was ₹25.57 crore, up from ₹22.40 crore YoY (14.19% growth).
EBITDA margin per kg improved to ₹46.68, up ₹6 YoY.
Finance costs increased by 20% quarter-on-quarter and 38% YoY, mainly due to higher working capital needs.
Outlook and guidance
Management targets 10–12% volume growth for FY2027, with double-digit growth in paints and strong momentum in food, FMCG, and pharma.
EBITDA per kg is projected to remain above ₹44–₹45 for the year, surpassing earlier guidance.
Expansion into new geographies and high-margin areas like ophthalmic packs, medical devices, and semiconductor packaging is planned.
Continued focus on R&D, automation, and innovation to drive value and resilience.
Paint segment's revenue share expected to decline as food, FMCG, and pharma outpace paint growth.
Latest events from Mold-Tek Packaging
- Sales and EBITDA rose, but net profit fell due to higher costs; capacity expansions underway.533080
Q2 24/25 - Q1 volumes and sales grew, but higher costs and new plant ramp-up impacted profitability.533080
Q1 24/25 - Q3 FY25 saw strong revenue and EBITDA growth, but PAT fell on higher costs; pharma and exports are rising.533080
Q3 24/25 - Revenue and EBITDA rose, but net profit declined as costs increased; pharma and FMCG led growth.533080
Q4 24/25 - Q1FY26 saw 22% revenue growth and 35.5% profit rise, led by pharma and FMCG momentum.533080
Q1 25/26 - H1FY26 revenue up 16.05% and PAT up 24%, led by strong pharma and FMCG growth.533080
Q2 25/26 - EBITDA and PAT up nearly 20% YoY, led by pharma and FMCG growth, with strong outlook.533080
Q3 25/26 - EBITDA and PAT grew over 20% YoY, with robust Pharma and FMCG segment growth and strong FY27 outlook.533080
Q4 25/26